Article Information
PubMed
Published By
History
- Received September 6, 2016
- Revision received November 16, 2016
- Accepted December 7, 2016
- Published online December 12, 2016.
Copyright & Usage
Copyright © 2016 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- Xingxing Wang1,2,3,*,
- Yuichi Sekine1,2,3,*,
- Alexandra B. Byrne1,2,4,
- William B.J. Cafferty3,
- Marc Hammarlund1,2,4 and
- Stephen M. Strittmatter1,2,3
- 1Program in Cellular Neuroscience, Neurodegeneration & Repair, Yale University School of Medicine, New Haven, CT 06536
- 2Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06520
- 3Department of Neurology, Yale University School of Medicine, New Haven, CT 06520
- 4Department of Genetics, Yale University School of Medicine, New Haven CT 06520
- Correspondence should be addressed to Stephen M. Strittmatter, CNNR Program, BCMM 436, Yale University School of Medicine, 295 Congress Ave., New Haven, CT 06536. E-mail: stephen.strittmatter{at}yale.edu.
Author contributions
Author Contributions: X.W. and Y.S. performed experiments and collected data. A.B., W.C., M.H., and S.M.S. designed experiments. X.W., Y.S., and S.M.S. analyzed data and wrote the paper.
↵* X.W. and Y.S. contributed equally to this work.
Disclosures
Conflicts of Interest: S.M.S. is a co-founder of Axerion Therapeutics seeking to develop NgR1-based therapeutics.
This work was supported by grants from NIH and Falk Medical Research Trust to S.M.S.
Funding
NINDS
R01NS080388Falk Medical Research Trust
NINDS
R01NS098817
Other Version
- You are viewing the most recent version of this article.
- previous version (December 12, 2016).
Online Impact